GenSci was established in 1997 and is a subsidiary of Changchun High tech Industry (Group) Co., Ltd. Its administrative and production headquarters are located in Changchun, its marketing headquarters are located in Shanghai, and its research and development headquarters are located in Shanghai, Beijing, and Changchun. The company integrates independent research and development, production, marketing, and service, and is the only genetic engineering new drug incubation base in the national "11th Five Year Plan" major new drug creation special project. It is the first genetic engineering drug quality management demonstration center in China, the only genetic engineering pharmaceutical enterprise in the world with PEG long acting growth hormone, and the winner of the second prize of the National Science and Technology Progress Award, It is also a globally renowned biopharmaceutical enterprise in the field of children's and women's health. The company will continue to move from a biopharmaceutical enterprise to an international technology service company that integrates biopharmaceuticals, medical devices, diagnostic reagents, and artificial intelligence.

GenSci is committed to providing integrated solutions for screening, testing, prevention, treatment, and rehabilitation throughout the entire human life cycle. By utilizing differentiation strategies, Jinsai focuses on disease fields with unique clinical needs and value, and deepens its development to create core R&D technology platforms with global advantages such as special formulations, live bacterial drug technology, NK Cell Engage, and AI drug design. At the same time, the annual R&D investment continues to increase by breaking through 15% of sales revenue. In 2021 alone, the R&D investment reached 1.36 billion yuan.

GenSci focuses on issues such as life health and intelligent drug development. Conduct drug design and screening through Discovery Studio software.